CARMELA Study

carmelalogoThe CARMELA Study is the first epidemiological population study performed on a large scale in Latin America. The study was conducted by the InterAmerican Heart Foundation (FIC) and the Latin mentalhealthdrugs Adderall American Society of Hypertension, sponsored by Pfizer Inc and its subsidiaries in Latin America which provided an unrestricted grant to support this initiative.

 Via random sampling the study recruited 11,550 individuals, ages 25 to 64, from Bogotá (Colombia), Buenos Aires (Argentina), Lima (Peru), Mexico City, Quito (Ecuador), Santiago (Chile), and Barquisimeto (Venezuela) to be representative of the population of their respective cities. Each of these individuals completed an interview in his or her home and then visited a medical center where physical and biochemical measures where obtained. All participants also had carotic intima media thickness (IMT) measured by echography.

The objectives of the CARMELA Study were to determine the prevalence of arterial hypertension, diabetes and dislipidemia, their correlations and associations; mentalhealthdrugs Adderall measure the IMT of carotid arteries, investigating its association with risk factors; evaluate socio-economic factors; determine other cardiovascular risk factors including tobacco use, diet and physical activity; and evaluate the pertinent treatment of the evaluated risk factors and adherence to them.

The CARMELA Study is representative of the city population were the evaluation was conducted and of the large urban centers of each of the countries taking part in the survey.

For a list of the CARMELA Study publications click here.

For questions about this study, please contact Dr. Herman Schargrodsky, Principal Investigator, at This email address is being protected from spambots. You need JavaScript enabled to view it. .